Actively Recruiting
QTX3034 in Patients With KRAS G12D Mutation
Led by Quanta Therapeutics · Updated on 2026-04-27
250
Participants Needed
14
Research Sites
164 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.
CONDITIONS
Official Title
QTX3034 in Patients With KRAS G12D Mutation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically documented, locally advanced or metastatic malignancy with KRAS G12D mutation confirmed by molecular testing (NGS- or PCR-based) in a certified diagnostic lab
- For Part 1: Advanced solid tumors with at least 1 prior systemic therapy
- Evaluable or measurable disease per RECIST 1.1 for Part 1
- Measurable disease per RECIST 1.1 for Parts 2 and 3
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Adequate organ function
You will not qualify if you...
- Prior treatment with a KRAS inhibitor
- Active brain metastases or carcinomatous meningitis
- History of other malignancy within 2 years
- Significant cardiovascular disease
- Disease or disorder that may pose a risk to patient's safety
- Other protocol-defined inclusion/exclusion criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 14 locations
1
UCLA Hematology/Oncology
Los Angeles, California, United States, 90095
Actively Recruiting
2
Sarah Cannon Research Institute (SCRI)
Denver, Colorado, United States, 80218
Actively Recruiting
3
Yale Cancer Center
New Haven, Connecticut, United States, 06511
Actively Recruiting
4
Florida Cancer Specialists
Sarasota, Florida, United States, 34232
Actively Recruiting
5
Moffitt Cancer Center
Tampa, Florida, United States, 33612
Actively Recruiting
6
NYU Langone Health
New York, New York, United States, 10016
Actively Recruiting
7
Montefiore Medical Center
The Bronx, New York, United States, 10461
Actively Recruiting
8
Duke University
Durham, North Carolina, United States, 27710
Actively Recruiting
9
Stephenson Cancer Center
Oklahoma City, Oklahoma, United States, 73104
Actively Recruiting
10
SCRI- Nashville
Nashville, Tennessee, United States, 37203
Actively Recruiting
11
MD Anderson
Houston, Texas, United States, 77030
Actively Recruiting
12
START San Antonio, LLC
San Antonio, Texas, United States, 78229
Actively Recruiting
13
University of Utah, Huntsman Cancer Center
Salt Lake City, Utah, United States, 84112
Actively Recruiting
14
NEXT Oncology Virginia
Fairfax, Virginia, United States, 22031
Actively Recruiting
Research Team
Q
Quanta Therapeutics Clinical Trials
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here